Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction
Articolo
Data di Pubblicazione:
2020
Abstract:
Two pharmaceutical agents have been approved for treatment of idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Body mass index; Idiopathic pulmonary fibrosis; Nintedanib; Therapy
Elenco autori:
Harari, Sergio; Specchia, Claudia; Lipsi, Roberto; Cassandro, Roberto; Caminati, Antonella
Link alla scheda completa:
Pubblicato in: